Is CA-125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma?
- 김시형; 김영환; 이희정
- Alternative Author(s)
- Kim, See Hyung; Kim, Young Hwan; Lee, Hee Jung
- Publication Year
- Background: Borderline ovarian tumors (BOTs) are difficult to differentiate from stage I carcinoma using
radiological findings. Little is known about the correlation between CA-125 levels and radiological findings
for predicting BOTs or carcinoma.
Purpose: To assess the role of CA-125, in addition to that of radiological findings, in differentiating BOTs
from stage I carcinoma.
Material and Methods: The study received institutional review board approval, with waiver of informed
consent. We evaluated 100 patients (two groups: BOT, 58 patients; stage I carcinoma, 42 patients) using
radiological findings, including location and size of each tumor, number and size of septations, papillary
projections and vegetations, peritoneal implants, ascites, and preoperative CA-125 levels. The differences in
CA-125 levels according to bilateral location, solid components, and thickness of septations between the
two groups were evaluated using the McNemar test. Correlations of CA-125 level to size and number of
septations were evaluated by the independent sample t test.
Results: No statistical correlation was found between CA-125 level and location, size, and number of
septations between the two groups. Solid components within the tumors were similar in the two groups, but
the CA-125 level was significantly higher in stage I carcinoma than in BOTs. The number of septations per
tumor was similar in the two groups; thick septations were more frequent in stage I carcinoma than in BOTs,
and a significantly higher titer of CA-125 was found in stage I carcinoma. Discriminant analysis of solid
components and thickness of septations resulted in accurate diagnosis of 70.6% of the tumors (80.6% of
BOTs and 69.7% of stage I carcinomas).
Conclusion: CA-125 levels for solid components and thickness of septations are lower in BOTs. These may
be helpful in predicting the risk of carcinoma, even if BOTs cannot be conclusively differentiated from stage I
Keywords: Borderline ovarian tumors, stage I carcinoma, CT, MRI, CA-125
- Authorize & License
- Files in This Item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.